Navigation Links
Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio

MADISON, Wis., May 7 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), the world's largest producer of cellular tools for drug discovery and safety derived from induced pluripotent stem cells (iPSCs), and iPS Academia Japan, Inc., today announced a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka, M.D., Ph.D., Center for iPS Cell Research and Application (CiRA), Kyoto University. CDI is the first company worldwide licensed to access the key patents surrounding iPSC technology from the two stem cell pioneers, Dr. Yamanaka and Dr. James A. Thomson, Ph.D., University of Wisconsin-Madison.

Dr. Thomson, founder and Chief Scientific Officer of CDI, and Dr. Yamanaka concurrently published in Science and Cell, respectively, in 2007 on their breakthrough iPSC research, whereby they turned ordinary human skin cells into pluripotent stem cells, with the same characteristics and potential as embryonic stem cells. Their patent portfolios are held by the Wisconsin Alumni Research Foundation (WARF), UW-Madison's tech transfer vehicle, and iPS Academia Japan, which manages the intellectual property related to methods of creating iPS cells from Kyoto University, respectively. Access to both these patent portfolios, in addition to CDI's previously disclosed IP, further establishes the company as the leader in iPSC technology.  Under this business arrangement, iPS Academia Japan will receive considerations and running royalties from CDI.  Both iPS Academia Japan and CDI expect stronger business relations between the parties in the developing field of iPS cell technologies.  

CDI, who commercially launched iCell™ Cardiomyocytes, human heart cells derived from iPSCs, last December, is the only company outside of Japan that iPS Academia Japan has granted licensing to the Kyoto University  iPSC patent portfolio. iCell Cardiomyocytes are used by the pharmaceutical industry to test new drug candidates, flagging ineffective or potentially toxic drug compounds early in the drug discovery process. The company plans to release several additional cell types, including liver, neural, and blood vessel cells, in the next 12 to 18 months for drug discovery and safety research.

Chris Parker, vice president and Chief Commercial Officer of CDI, stated, "CDI is actively searching to license commercially useful iPSC technologies, and this license further strengthens our growing patent portfolio and our position in the market.  Our strong IP helps position us as a preferred collaborator and provider to pharmaceutical and biotech companies developing drug discovery and safety tools to aid the industry."

Dr. Yamanaka commented, "I am very pleased that Dr. Thomson's company, CDI, has licensed my patents.  His company is working to make the benefits of iPSC technology widely available to drug researchers worldwide, a goal I share as we work toward the improvement of human healthcare.  I would hope that this is the beginning for iPS cell technologies to be developed by many scientists and business organizations worldwide. "

"My esteemed colleague, Dr. Yamanaka, and I both are working towards the widespread availability of iPSC technology and the promise it holds for improving healthcare," said Dr. Thomson.  "Stem cells have such great potential — to find the root cause of disease, to test new drugs at the human cellular level, and to eventually impact individual healthcare. This agreement sets the stage for a partnership that will foster collaboration to move our technology forward."

Osamu Yoshida, M.D., Ph.D., president and Chief Executive Officer of iPS Academia Japan, commented, "It is Professor Yamanaka's desire, as well as ours, to see the application of this technology be utilized broadly to benefit health and well-being of all people.  We are pleased to work with a company the caliber of Cellular Dynamics, who has already made great strides in making use of iPS cells to benefit healthcare."

Robert Palay, CDI's chairman and Chief Executive Officer, said, "We are thrilled about the license agreement with IPS Academia Japan.   We see this as a first step to further collaborations between iPS Academia Japan and Cellular Dynamics International."

About Cellular Dynamics International

Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund.  CDI's facilities are located in Madison, Wisconsin.  See

About iPS Academia Japan, Inc.

iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is, among other activities, to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other universities in the field of iPS cell technologies so that the research results might contribute to health and welfare worldwide.  AJ was established at Kyoto on June 2008.  AJ's patents portfolio consists of approximately twenty patent families in the iPS cell technology as of April 2010. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
3. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
6. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)
9. Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
10. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
11. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
Post Your Comments:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is a ... filling out a survey; in many cases health professionals and patients are working together ... research on the importance of active engagement with patients and members of the public ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
Breaking Medicine News(10 mins):